# A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

> **NCT06571266** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 231 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT06571266
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-11
- **Primary completion:** 2025-04-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571266, "A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06571266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*